Array BioPharmaStock Price and Value Analysis

Should you buy Array BioPharma stock? (NasdaqGM:ARRY). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

ARRY Free Cash Flow Trend

Hmm, we can't give any reliable projection for Array BioPharma's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for ARRY
Free Cash Flow trendline for Array BioPharma

Inside the ARRY Numbers

ARRY Price
(Array BioPharma stock price per share)
$11.25
[?] PE Ratio versus Sector 369% higher than other Healthcare stocks
[?] PE Ratio versus Industry 64% higher than other Biotechnology stocks
[?] Cash Yield -0.21%
[?] Free Cash Flow Jitter 79%

Is Array BioPharma Stock on Sale?

Based on our analysis, we believe that you should not buy Array BioPharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ARRY Stock?

Does Array BioPharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.